Thomas Eugene Rowe

US Patent:

20120164213, Jun 28, 2012

Filed:

Jun 18, 2010

Appl. No.:

13/378335

Inventors:

Clive H. Reading - Kent, GB
Thomas Rowe - Roswell GA, US
Mario G. Fsadni - Hertfordshire, GB
Rick Coulon - Cummings GA, US

Assignee:

Altos Vision Limited - Kent

International Classification:

A61K 9/127
A61P 27/02
A61P 29/00
A61K 31/56

US Classification:

424450, 514170, 514171, 514182

Abstract:

A topical application formulation of estrogen and estrogen analogs or other estrogen receptor modulators is disclosed for the treatment of primary or secondary dry eye syndrome (also known as keratoconjunctivitis sicca (KCS)). Preferred formulations include 17-β-estradiol and its derivatives in lipid, liposomes, polymers, or aqueous or non-aqueous vehicles for the topical treatment of the ocular surface tissues particularly as time-release or micro-dose formulations. These formulations may also be useful in treating other conditions where KCS may occur, such as post-operative refractive surgery and corneal transplant patients.

US Patent:

56114648, Mar 18, 1997

Filed:

May 30, 1995

Appl. No.:

8/449476

Inventors:

Stephen M. Martin - Roswell GA
Harold Shlevin - Marietta GA
Thomas E. Rowe - Roswell GA

Assignee:

CIBA Geigy Corporation - Tarrytown NY

International Classification:

B67D 558

US Classification:

22218906

Abstract:

A container, composition and method for preserving treatment solutions, in which the composition includes weak and strong preservatives. The dispensing container includes media within a dispensing tip which media removes or alters the strong preservative, while allowing the weak preservative to inhibit microbial growth in the tip media. The dispensing container is especially useful in delivering to the ocular environment ophthalmic solutions which are essentially free of strong preservative which may cause patient discomfort. A dispensing container including a pH-preserved pilocarpine solution is disclosed in one embodiment.

US Patent:

58635629, Jan 26, 1999

Filed:

Mar 29, 1996

Appl. No.:

8/626198

Inventors:

Stephen Merritt Martin - Roswell GA
Harold Shlevin - Marietta GA
Thomas Edward Rowe - Roswell GA

Assignee:

CIBA Vision Corporation - Duluth GA

International Classification:

A61K 3340

US Classification:

424616

Abstract:

A container, composition and method for preserving treatment solutions, in which the composition includes weak and strong preservatives. The dispensing container includes media within a dispensing tip which media removes or alters the strong preservative, while allowing the weak preservative to inhibit microbial growth in the tip media. The dispensing container is especially useful in delivering to the ocular environment ophthalmic solutions which are essentially free of strong preservative which may cause patient discomfort. A dispensing container including a pH-preserved pilocarpine solution is disclosed in one embodiment.

US Patent:

20200390695, Dec 17, 2020

Filed:

Aug 27, 2020

Appl. No.:

17/005196

Inventors:

- Stockholm, SE
Thomas ROWE - Roswell GA, US
Mario G. FSADNI - Hertfordshire, GB
Richard COULON - Cummings GA, US

International Classification:

A61K 9/00
A61K 31/568
A61K 31/5685
A61K 45/06
A61K 47/32
A61K 47/36
A61K 47/40
A61K 31/565
A61K 31/566

Abstract:

A topical application formulation of estrogen and estrogen analogs or other estrogen receptor modulators is disclosed for the treatment of primary or secondary dry eye syndrome (also known as keratoconjunctivitis sicca (KCS)). Preferred formulations include 17-β-estradiol and its derivatives in lipid, liposomes, polymers, or aqueous or non-aqueous vehicles for the topical treatment of the ocular surface tissues particularly as time-release or micro-dose formulations. These formulations may also be useful in treating other conditions where KCS may occur, such as post-operative refractive surgery and corneal transplant patients.

US Patent:

20180263901, Sep 20, 2018

Filed:

May 21, 2018

Appl. No.:

15/985554

Inventors:

- Stockholm, SE
Thomas ROWE - Roswell GA, US
Mario G. FSADNI - Hertfordshire, GB
Richard COULON - Cummings GA, US

International Classification:

A61K 9/00
A61K 31/566
A61K 45/06
A61K 31/568
A61K 31/565
A61K 31/5685
A61K 47/32
A61K 47/36
A61K 47/40

Abstract:

A topical application formulation of estrogen and estrogen analogs or other estrogen receptor modulators is disclosed for the treatment of primary or secondary dry eye syndrome (also known as keratoconjunctivitis sicca (KCS)). Preferred formulations include 17-β-estradiol and its derivatives in lipid, liposomes, polymers, or aqueous or non-aqueous vehicles for the topical treatment of the ocular surface tissues particularly as time-release or micro-dose formulations. These formulations may also be useful in treating other conditions where KCS may occur, such as post-operative refractive surgery and corneal transplant patients.